Product Description
BLU-808 is an oral, highly potent and selective wild-type KIT inhibitor with first- and best-in-class potential, as a development candidate for the treatment of mast cell disorders, including chronic urticaria. (Sourced from: https://www.benzinga.com/pressreleases/23/08/n33516923/blueprint-medicines-reports-second-quarter-2023-results)
Mechanisms of Action: C-KIT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Blueprint Medicines
Company Location: CAMBRIDGE MA 02139
Company CEO: Kathryn Haviland
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Blueprint Medicines presented P1 Healthy Volunteers results on 2025-03-02 for BLU-808
- Clinical Outcomes Reported - Blueprint Medicines presented P0 Urticaria|Mastocytosis results on 2024-02-23 for BLU-808
- Clinical Outcomes Reported - Blueprint Medicines presented P0 Chronic Spontaneous Urticaria results on 2024-02-23 for BLU-808
Highest Development Phases
Phase 2: Chronic Inducible Urticaria|Chronic Spontaneous Urticaria|Conjunctivitis, Allergic
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| BLU-808-1201 | P2 |
Recruiting |
Chronic Spontaneous Urticaria|Chronic Inducible Urticaria |
2026-12-31 |
50% |
2025-06-04 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
| BLU-808-2201 | P2 |
Recruiting |
Conjunctivitis, Allergic |
2025-12-31 |
12% |
2025-05-03 |
|
| BLU-808-0101 | P1 |
Completed |
Healthy Volunteers |
2025-01-21 |
2025-04-30 |